Amphastar Pharmaceuticals, Inc.AMPH财报
Nasdaq · 医疗保健 · 药物制剂
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
营收
$182.4M
毛利润
$95.2M
营业利润
$55.2M
净利润
$37.9M
毛利率
52.2%
营业利润率
30.3%
净利率
20.8%
同比增长
25.2%
EPS
$0.73
Amphastar Pharmaceuticals, Inc. 2024财年Q2 财务摘要
Amphastar Pharmaceuticals, Inc. 2024财年Q2营收 $182.4M（同比增长 25.2%），净利润 $37.9M（同比增长 45.3%）（净利率 20.8%）。销售成本 $87.2M，运营费用 $39.9M。
核心财务指标
| 总营收 | $182.4M |
|---|---|
| 净利润 | $37.9M |
| 毛利率 | 52.2% |
| 营业利润率 | 30.3% |
| 报告期 | 2024财年Q2 |
营收拆解
Amphastar Pharmaceuticals, Inc. 2024财年Q2营收 $182.4M 共来自 11 个业务板块，最大板块 Other Finished Pharmaceutical Products 贡献 $34.7M（占 19.0%）。
| 业务分部 | 营收 | 占比 |
|---|---|---|
| Other Finished Pharmaceutical Products | $34.7M | 19.0% |
| Baqsimi | $30.9M | 16.9% |
| Epinephrine | $27.9M | 15.3% |
| Glucagon | $27.4M | 15.0% |
| Primatenemist | $22.9M | 12.5% |
| Lidocaine | $12.8M | 7.0% |
| Phytonadione | $10.3M | 5.6% |
| Enoxaparin | $5.3M | 2.9% |
| Active Pharmaceutical Ingredient Segment | $3.5M | 1.9% |
| Baqsimi Neb | $3.0M | 1.6% |
| Research And Development Services | $1.5M | 0.8% |
Amphastar Pharmaceuticals, Inc. 分部营收 — 季度趋势
Amphastar Pharmaceuticals, Inc. 过去 4 个季度各业务板块营收走势，展示 Other Finished Pharmaceutical Products和Baqsimi 等业务的变化。
| 业务分部 | 2025财年Q4 | 2025财年Q3 | 2025财年Q2 | 2025财年Q1 |
|---|---|---|---|---|
| Baqsimi | $46.7M | $53.6M | $46.7M | $38.4M |
| Epinephrine | $17.1M | $18.8M | $16.2M | $18.6M |
| Glucagon | $14.1M | $13.6M | $20.6M | $20.8M |
| Primatenemist | $27.9M | $28.8M | $22.9M | $29.1M |
Amphastar Pharmaceuticals, Inc. 年度营收
Amphastar Pharmaceuticals, Inc. 历年营收汇总，含各年度总量（例如 2025 年营收为 $719.9M）
| 年份 | 年营收 |
|---|---|
| 2025 | $719.9M |
| 2024 | $732.0M |
| 2023 | $644.4M |
| 2022 | $499.0M |
Amphastar Pharmaceuticals, Inc. 季度营收与净利润历史
Amphastar Pharmaceuticals, Inc. 最近 8 个季度的营收、净利润及同比增速
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| 2025财年Q4 | $183.1M | -1.8% | $24.4M | 13.3% |
| 2025财年Q3 | $191.8M | +0.3% | $17.4M | 9.0% |
| 2025财年Q2 | $174.4M | -4.4% | $31.0M | 17.8% |
| 2025财年Q1 | $170.5M | -0.8% | $25.3M | 14.8% |
| 2024财年Q4 | $186.5M | +4.7% | $38.0M | 20.4% |
| 2024财年Q3 | $191.2M | +5.9% | $40.4M | 21.1% |
| 2024财年Q2 | $182.4M | +25.2% | $37.9M | 20.8% |
| 2024财年Q1 | $171.8M | +22.7% | $43.2M | 25.1% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $171.8M | $182.4M | $191.2M | $186.5M | $170.5M | $174.4M | $191.8M | $183.1M |
| 同比增长 | 22.7% | 25.2% | 5.9% | 4.7% | -0.8% | -4.4% | 0.3% | -1.8% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $1.57B | $1.49B | $1.55B | $1.58B | $1.63B | $1.62B | $1.67B | $1.63B |
| 总负债 | $902.0M | $778.2M | $817.5M | $845.2M | $875.0M | $857.9M | $889.5M | $840.5M |
| 股东权益 | $672.4M | $713.3M | $727.7M | $732.3M | $751.3M | $757.5M | $776.7M | $788.8M |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $55.3M | $69.1M | $60.0M | $29.0M | $35.1M | $35.6M | $52.6M | $32.9M |